The Association Between CYP2C19 Genotype and of In-stent Restenosis Among Patients with Vertebral Artery Stent Treatment
The Association Between CYP2C19 Genotype and of In-stent Restenosis Among Patients with Vertebral Artery Stent Treatment
复制标题
CYP2C19基因型与椎动脉支架治疗患者支架内再狭窄的相关性
DOI：
10.1111/cns.12173
复制
发表时间：
2014-02-01
影响因子：
5.5
通讯作者：
Xu, Yun
中科院分区：
文献类型：
--
作者：
Lin, Yong-Juan;Li, Jing-Wei;Xu, Yun
由于支架内再狭窄的发生，通过椎动脉支架血管内治疗预防脑卒中仍然是一个巨大的挑战。材料与方法本研究对南京鼓楼医院2004年至2011年期间接受VAS治疗的90例患者进行回顾性分析。在VAS治疗后3个月、6个月和1年对患者进行随访，此后每年随访一次。每个时间点均进行神经功能检查、血管超声和计算机断层血管造影，初步筛查血管狭窄情况。数字减影血管造影用于验证 CTA 或超声上的狭窄征象。记录每位患者的临床特征，包括氯吡格雷代谢基因（CYP2C19、CYP3A4和P2Y12），旨在探讨发生ISR的可能危险因素。结果单因素分析显示高脂血症（P
AimsPreventing stroke through endovascular treatment with vertebral artery stent remains a great challenge due to the occurrence of an in-stent restenosis.Materials & MethodsIn this study, a retrospective analysis was conducted in 90 patients who had been treated with VAS between 2004 and 2011 in Nanjing Drum Tower Hospital. Patients were followed up at 3months, 6months,and 1year after VAS treatment and annually thereafter. For each time point, neurological function tests, vessel ultrasound and computer tomography angiography were performed to preliminarily screen the vessel stenosis. Digital subtraction angiography was used to verify the narrow sign on CTA or ultrasound. Clinical features of each patient including clopido-grel metabolization genes (CYP2C19, CYP3A4, and P2Y12) were recorded with purpose to investigate the possible risk factors for the development of ISR.ResultsSingle factor analysis dem-onstrated that hyperlipidemia (P